Pharmanutra Pharmanutra S.p.A.: First Significant Sales Results in China Stock: price and insider trades · Italy
Pharmanutra Pharmanutra S.p.A.: First Significant Sales Results in China: what insiders have been doing
We have very little insider data for Pharmanutra Pharmanutra S.p.A.: First Significant Sales Results in China so far: the most recent filing dates from 18 November 2024. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 8,122 of 26,911 companies
61.5
score / 100
Value38
Quality85
FCF yld2.1%
Earn yld2.5%
EV/EBITDA23.8x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€83.00
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-2%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.7x
PER (forward)27.1x
P/Book10.7x
Beta0.17
Balance sheet & cash
Market cap€794.7M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 18 November 2024
Declarations1 total
- ●Executives0Consob
1 of 1 declaration
About Pharmanutra Pharmanutra S.p.A.: First Significant Sales Results in China
Pharmanutra S.p.a. is a company focused on the health and pharmaceutical sector. It recently reported its first significant sales results in China.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
